Effectiveness and Safety of First-Line Non-Bismuth Quadruple Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapy
Loading...
Identifiers
Publication date
Authors
Nyssen, Olga P.
Montes, Nuria
Pérez Aísa, Ángeles
Martínez Domínguez, Samuel J.
Tejedor Tejada, Javier
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SDG
Metrics
Abstract
The V Spanish Consensus Conference on Helicobacter pylori recommended either a 14-day non-bismuth quadruple concomitant therapy (CT: proton pump inhibitor [PPI], clarithromycin, amoxicillin, and metronidazole) or a 10-day bismuth-containing quadruple therapy (Sc-BQT: PPI, bismuth, tetracycline, and metronidazole in a single capsule). The relative advantages of each remain uncertain.
Sc-BQT is more effective, better tolerated, and more broadly applicable than 14-day CT. Both regimens achieved ≥ 90% success, but Sc-BQT's stewardship-friendly profile further supports its use as first-line therapy for H. pylori eradication.
Description
UNESCO Subjects
Keywords
Bibliographic reference
Nyssen, O. P., Montes, N., Pérez‐Aísa, Á., Martínez‐Domínguez, S. J., Tejedor‐Tejada, J., Lucendo, A. J., Huguet, J. M., Garre, A., Bujanda, L., Pabón‐Carrasco, M., Castro‐Fernández, M., Perona, M., Ortiz‐Polo, I., Núñez, Ó., Marcos, M. S., Gómez Rodríguez, B. J., Loro, A. M., Bermejo, F., Barrio, J., … the Hp‐EuReg investigators. (2025). Effectiveness and safety of first‐line non‐bismuth quadruple concomitant therapy versus single‐capsule bismuth quadruple therapy. Alimentary Pharmacology & Therapeutics, 62(8), 809-820. https://doi.org/10.1111/apt.70261